ReviewCancers2022
Treatment of Resectable Gallbladder Cancer.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Gallbladder carcinoma in Brazil: Clinicopathological profile and survival outcomes from a high-volume cancer center.World journal of gastroenterology · 2026Article
- Gallbladder and biliary tract cancer burden trends in Brazil, Russian Federation, India, China, and South Africa in 1990-2021.World journal of gastrointestinal oncology · 2025Article
- Dynamic gene expression pattern in zebrafish gallbladder: an experimental study.International journal of surgery (London, England) · 2024Article
- A Single-Center Analysis of Patient Characteristics and Overall Survival in Patients with Resectable Gallbladder Cancer.Healthcare (Basel, Switzerland) · 2024Article
- Novel multifactor predictive model for postoperative survival in gallbladder cancer: a multi-center study.World journal of surgical oncology · 2024Article
- Article
- Parthenolide induces gallbladder cancer cell apoptosis via MAPK signalling.Annals of medicine and surgery (2012) · 2024Article
- Benchmarks and Geographic Differences in Gallbladder Cancer Surgery: An International Multicenter Study.Annals of surgical oncology · 2023Article
- Application and Progress of Cultured Models of Gallbladder Carcinoma.Journal of clinical and translational hepatology · 2023Review
- Article
- Residual cancer is a strong predictor of survival in T3 incidental gallbladder cancer.BMC surgery · 2022Article
- Publication Trends of Research on Gallbladder Cancer During 2001-2021: A 20-Year Bibliometric Analysis.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gallbladder cancer (GBC) is the most common biliary tract cancer worldwide and its incidence has significant geographic variation. A unique combination of predisposing factors includes genetic predisposition, geographic distribution, female gender, chronic inflammation, and congenital developmental abnormalities. Today, incidental GBC is the most common presentation of resectable gallbladder cancer, and surgery (minimally invasive or open) remains the only curative treatment available. Encouragingly, there is an important emerging role for systemic treatment for patients who have R1 resection or present with stage III-IV. In this article, we describe the pathogenesis, surgical and systemic treatment, and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.